Navigating Injection Device Selection: Translating Pharma Drivers into Development Decisions
Day 1 Packaging & Device Innovation Stage
06/10/2026 14:45 - 15:10pm
Contributors
Adam Stops : Senior Director of Product Management, Drug Delivery Systems - Stevanato Group
Rahel von Rohr : Director, Device Development – Head of Kymanox Europe - Kymanox
Beyond considerations of safe and effective delivery to the patient, strategic device selection plays a key role in de-risking development timelines, controlling costs, and enabling successful commercialization and portfolio scale-up.Building on this context, the first part of the presentation will discuss processes and tools that support the selection of the “right” injection device for a given combination product program and portfolio. It will explore the broad range of selection criteria involved and how their relative weighting may vary depending on a company’s setup and strategy, with no one-size-fits-all solution.
The second part of the presentation will introduce a case study illustrating how these factors can be addressed by device manufacturers in the development of a new platform. In particular, it will demonstrate how commercial relevance can be achieved by aligning with key selection criteria of pharma partners.The presentation will conclude by showing how this approach, once validated, can be consistently applied to guide the development of subsequent platforms, establishing a repeatable innovation framework that remains adaptable to evolving pharma needs and market contexts.